DUPIXENT does not require initial lab testing or ongoing lab monitoring, according to the Prescribing Information1

Available in a 200 mg or 300 mg pre-filled pen (for patients
12+ years of age) or pre-filled syringe (for 6+ months of age)
for subcutaneous injection

DUPIXENT is an injectable medicine that is administered by subcutaneous injection and is intended for use under the guidance of a healthcare provider.1
  • A patient may self-inject DUPIXENT—or a caregiver may administer DUPIXENT—after training has been provided by a healthcare provider on proper subcutaneous injection technique using the pre-filled syringe or pre-filled pen
    • The DUPIXENT pre-fill syringe should be given by a caregiver in children younger than 12 years of age
    • In adolescents 12 years of age and older, it is recommended that DUPIXENT be administered by or under the supervision of an adult
  • It is important to provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use
  • After administration, advise patients to follow sharps disposal recommendations
  • Patients and/or caregivers should read the Instructions for Use—either 200 mg or 300 mg pre-filled pen or pre-filled syringe—prior to injecting
  • Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with DUPIXENT

One dose every 2 or 4 weeks based on age and weight (after an initial loading dose of two
subcutaneous injections) in patients aged 6+ years. For patients aged 6 months to 5 years, one
dose every 4 weeks based on weight, with no initial loading dose recommended.1

Dosage for uncontrolled moderate-to-severe
atopic dermatitis

One dosage regimen in adults1

Initial Loading Dose:

600 mg

2 x 300 mg pre-filled pens or syringes

Weight-tiered dosage regimen in children and adolescents1,a,b

≥60 kg

Initial Loading Dose:

600 mg

2 x 300 mg pre-filled pens or syringes

30 to <60 kg

Initial Loading Dose:

400 mg

2 x 200 mg pre-filled pens or syringes

15 to <30 kg

Initial Loading Dose:

600 mg

2 x 300 mg pre-filled syringes

Weight-tiered dosage regimen in infants to preschoolers1,a

15 to <30 kg

No initial loading dose
recommended

5 to <15 kg

No initial loading dose
recommended

Q2W, once every 2 weeks; Q4W, once every 4 weeks.

a5 kg is equal to 11 lb; 15 kg is equal to 33 lb; 30 kg is equal to 66 lb; 60 kg is equal to 132 lb.

bThe DUPIXENT 200 mg and 300 mg pre-filled pens are approved for patients aged 12+ years.

At-home or in-office administration options

Important administration instructions1

  • Patients and/or caregivers should read the Instructions for Use prior to injecting
  • Instruct patients and/or caregivers to administer subcutaneous injection into the thigh or abdomen, except for the 2 inches (5 cm) around the navel
  • The upper arm can also be used if a caregiver administers the injection
  • It is important to rotate the injection site with each injection. DO NOT inject DUPIXENT into skin that is tender, damaged, bruised, or scarred
  • For the initial dose, patients and/or caregivers should administer each DUPIXENT injection at a different injection site
  • The DUPIXENT pre-filled syringe should be given by a caregiver in children younger than 12 years of age. In adolescents 12 years of age and older, it is recommended that DUPIXENT be administered by or under the supervision of an adult.

See the Instructions for Use for more detailed instructions on the preparation and administration of DUPIXENT

Pre-Filled Pen

Instructions for Use - 200 mg
Instructions for Use - 300 mg

Pre-Filled Syringe

Instructions for Use - 200 mg
Instructions for Use - 300 mg

Supplemental Injection Training

VIEW PATIENT VIDEOS

Outer
upper arms

Abdomen

Thighs

Injection by caregiver only

Self-injection or by caregiver

Preparation for Use1

Before injection, instruct patients and/or caregivers to remove the DUPIXENT pre-filled pen or syringe from the refrigerator and allow DUPIXENT to reach room temperature without removing the needle cap.

  • 45 minutes for the 300 mg/2 mL
    pre‑filled pen or syringe
  • 30 minutes for the 200 mg/1.14 mL pre-filled pen or syringe

Patients and/or caregivers should not use the pre-filled pen or syringe if the liquid contains visible particulate matter, or is discolored or cloudy (other than clear to slightly opalescent, colorless to pale yellow).

Patients and/or caregivers should discard any unused product remaining in the pre-filled pen or syringe in accordance with local requirements.

Dosage forms and
strengths1

DUPIXENT is a clear to slightly opalescent, colorless to pale yellow solution available as:

  • Injection: 300 mg/2 mL in a single-dose, pre-filled pen with hidden needle or syringe with needle shield
  • Injection: 200 mg/1.14 mL in a single-dose, pre-filled pen with hidden needle or syringe with needle shield

How it's supplied1

DUPIXENT is available in cartons containing 2 pre-filled pens or syringes with needle shields. Each 300 mg pre-filled syringe or pre-filled pen delivers 300 mg/2 mL. Each 200 mg pre-filled syringe or pre-filled pen delivers 200 mg/1.14 mL.

Storage and Handling1

  • DUPIXENT is sterile and preservative-free. Patients and/or caregivers should discard any unused portion
  • Patients and/or caregivers should store DUPIXENT by refrigerating at 36 °F to 46 °F (2 °C to 8 °C) in the original carton to protect from light
  • If necessary, pre-filled pens or syringes may be kept at room temperature up to 77 °F (25 °C) for a maximum of 14 days. DUPIXENT should not be stored above 77 °F (25 °C). After removal from the refrigerator, DUPIXENT must be used within 14 days or discarded
  • The pen or syringe should not be exposed to heat or direct sunlight
  • Any unused medicinal product or waste material should be disposed of in accordance with local requirements
  • Do NOT freeze. Do NOT expose to heat. Do NOT shake